Osteoarthritis: Osteoporotic OA: a reasonable target for bone-acting agents

Nat Rev Rheumatol. 2013 Aug;9(8):448-50. doi: 10.1038/nrrheum.2013.113. Epub 2013 Jul 16.


Beneficial effects of bone-acting drugs in osteoarthritis (OA) are increasingly reported, but reliable conclusions regarding their efficacy are hindered by methodological drawbacks in study design. Identifying patients with osteoporotic OA, a phenotype defined by decreased density associated with high remodelling in subchondral bone, might improve the success of bone-directed agents.

Publication types

  • News
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Density Conservation Agents / pharmacology
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Remodeling / drug effects
  • Diphosphonates / pharmacology
  • Diphosphonates / therapeutic use*
  • Humans
  • Osteoarthritis, Knee / drug therapy*
  • Osteoporosis / drug therapy*


  • Bone Density Conservation Agents
  • Diphosphonates